Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Molecular mechanisms and therapeutic targets for diabetic kidney disease
Katherine R. Tuttle, Rajiv Agarwal, Charles E. Alpers, et al.
Kidney International (2022) Vol. 102, Iss. 2, pp. 248-260
Open Access | Times Cited: 294

Showing 1-25 of 294 citing articles:

A Synopsis of the Evidence for the Science and Clinical Management of Cardiovascular-Kidney-Metabolic (CKM) Syndrome: A Scientific Statement From the American Heart Association
Chiadi E Ndumele, Ian J. Neeland, Katherine R. Tuttle, et al.
Circulation (2023) Vol. 148, Iss. 20, pp. 1636-1664
Open Access | Times Cited: 219
Diabetic Nephropathy: Update on Pillars of Therapy Slowing Progression
Sandra Naaman, George L. Bakris
Diabetes Care (2023) Vol. 46, Iss. 9, pp. 1574-1586
Open Access | Times Cited: 106
Efficacy and safety of aldosterone synthase inhibition with and without empagliflozin for chronic kidney disease: a randomised, controlled, phase 2 trial
Katherine R. Tuttle, Sibylle J. Hauske, María Eugênia Fernandes Canziani, et al.
The Lancet (2023) Vol. 403, Iss. 10424, pp. 379-390
Open Access | Times Cited: 63
Identification and validation of immune and oxidative stress-related diagnostic markers for diabetic nephropathy by WGCNA and machine learning
Mingming Xu, Hang Zhou, Ping Hu, et al.
Frontiers in Immunology (2023) Vol. 14
Open Access | Times Cited: 58
Effects of semaglutide with and without concomitant SGLT2 inhibitor use in participants with type 2 diabetes and chronic kidney disease in the FLOW trial
Johannes F.E. Mann, Peter Rossing, George L. Bakris, et al.
Nature Medicine (2024) Vol. 30, Iss. 10, pp. 2849-2856
Open Access | Times Cited: 49
Type 2 diabetes mellitus in adults: pathogenesis, prevention and therapy
Xi Lu, Qingxing Xie, Xiaohui Pan, et al.
Signal Transduction and Targeted Therapy (2024) Vol. 9, Iss. 1
Open Access | Times Cited: 39
Oxidative Stress: A Culprit in the Progression of Diabetic Kidney Disease
Na Wang, Chun Zhang
Antioxidants (2024) Vol. 13, Iss. 4, pp. 455-455
Open Access | Times Cited: 36
Recent Advances in the Management of Diabetic Kidney Disease: Slowing Progression
Na Wang, Chun Zhang
International Journal of Molecular Sciences (2024) Vol. 25, Iss. 6, pp. 3086-3086
Open Access | Times Cited: 22
Cardiovascular and Kidney Risks in Individuals With Type 2 Diabetes: Contemporary Understanding With Greater Emphasis on Excess Adiposity
Naveed Sattar, Calum Presslie, Martin K. Rutter, et al.
Diabetes Care (2024) Vol. 47, Iss. 4, pp. 531-543
Open Access | Times Cited: 18
Diabetes and Renal Complications: An Overview on Pathophysiology, Biomarkers and Therapeutic Interventions
Rajesh Kumar Jha, Sara Lopez-Trevino, Haritha R. Kankanamalage, et al.
Biomedicines (2024) Vol. 12, Iss. 5, pp. 1098-1098
Open Access | Times Cited: 17
LOX-induced tubulointerstitial fibrosis via the TGF-β/LOX/Snail axis in diabetic mice
Yicheng Lu, Heyangzi Li, Mohan Chen, et al.
Journal of Translational Medicine (2025) Vol. 23, Iss. 1
Open Access | Times Cited: 2
Mechanisms, Biomarkers, and Treatment Approaches for Diabetic Kidney Disease: Current Insights and Future Perspectives
Jean Paule Joumaa, Angela Raffoul, Claudia Sarkis, et al.
Journal of Clinical Medicine (2025) Vol. 14, Iss. 3, pp. 727-727
Open Access | Times Cited: 2
Targeting the NF-κB p65-MMP28 axis: Wogonoside as a novel therapeutic agent for attenuating podocyte injury in diabetic nephropathy
Xiandeng Li, Shuyan Zhao, Jing Xie, et al.
Phytomedicine (2025) Vol. 138, pp. 156406-156406
Open Access | Times Cited: 2
Molecular Mechanisms of Diabetic Kidney Disease
Jorge Rico-Fontalvo, Gustavo Aroca, José Cabrales, et al.
International Journal of Molecular Sciences (2022) Vol. 23, Iss. 15, pp. 8668-8668
Open Access | Times Cited: 53
What’s New in the Molecular Mechanisms of Diabetic Kidney Disease: Recent Advances
Kimio Watanabe, Emiko Sato, Eikan Mishima, et al.
International Journal of Molecular Sciences (2022) Vol. 24, Iss. 1, pp. 570-570
Open Access | Times Cited: 48
FTZ polysaccharides ameliorate kidney injury in diabetic mice by regulating gut-kidney axis
Tian Lan, Tang Tang, Ying Li, et al.
Phytomedicine (2023) Vol. 118, pp. 154935-154935
Closed Access | Times Cited: 33
The Interplay between Immune and Metabolic Pathways in Kidney Disease
Lili Qu, Baihai Jiao
Cells (2023) Vol. 12, Iss. 12, pp. 1584-1584
Open Access | Times Cited: 30
Astragalus membranaceus and Salvia miltiorrhiza ameliorate diabetic kidney disease via the “gut-kidney axis”
Zhen Shen, Tao Cui, Yao Liu, et al.
Phytomedicine (2023) Vol. 121, pp. 155129-155129
Closed Access | Times Cited: 30
Osteopontin as a Biomarker in Chronic Kidney Disease
Satyesh K. Sinha, Michael Mellody, Maria Beatriz Carpio, et al.
Biomedicines (2023) Vol. 11, Iss. 5, pp. 1356-1356
Open Access | Times Cited: 29
Single-cell transcriptomic profiles in the pathophysiology within the microenvironment of early diabetic kidney disease
Yi‐Chun Tsai, Mei‐Chuan Kuo, Juan-Chi Huang, et al.
Cell Death and Disease (2023) Vol. 14, Iss. 7
Open Access | Times Cited: 27
The role of the farnesoid X receptor in kidney health and disease: a potential therapeutic target in kidney diseases
Dong-Hyun Kim, Jung Sun Park, Hoon‐In Choi, et al.
Experimental & Molecular Medicine (2023) Vol. 55, Iss. 2, pp. 304-312
Open Access | Times Cited: 26
Oxidative stress as a culprit in diabetic kidney disease
Sensen Su, Zhanchuan Ma, Hao Wu, et al.
Life Sciences (2023) Vol. 322, pp. 121661-121661
Closed Access | Times Cited: 26
Non-steroidal mineralocorticoid receptor antagonist finerenone ameliorates mitochondrial dysfunction via PI3K/Akt/eNOS signaling pathway in diabetic tubulopathy
Lan Yao, Xianhui Liang, Yamin Liu, et al.
Redox Biology (2023) Vol. 68, pp. 102946-102946
Open Access | Times Cited: 26
Biomarkers to Guide Medical Therapy in Primary Aldosteronism
Gregory L. Hundemer, Alexander A. C. Leung, Gregory Kline, et al.
Endocrine Reviews (2023) Vol. 45, Iss. 1, pp. 69-94
Open Access | Times Cited: 25
The roles of gut microbiota and its metabolites in diabetic nephropathy
Hui Zhao, Cheng-E Yang, Tian Liu, et al.
Frontiers in Microbiology (2023) Vol. 14
Open Access | Times Cited: 25
Page 1 - Next Page

Scroll to top